Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CochlearCHEOY -2.45%68 3-1 Month Momentum % is 25.04% as of Sep. 21, 2026. GuruFocus rates CHEOY with a GF Score™ of 68/100 and a GF Value™ of $105.08 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 847 Medical Devices & Instruments companies, Cochlear ranks better than 87.49% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-21), Cochlear's 3-1 Month Momentum % is 25.04%.
The industry rank for Cochlear's 3-1 Month Momentum % or its related term are showing as below:
CHEOY's 3-1 Month Momentum % is ranked better than 87.49% of 847
companies
in the Medical Devices & Instruments industry
Industry Median: 0.61
vs CHEOY: 25.04
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Cochlear 3-1 Month Momentum % Related Terms
CHEOY vs ABT, SYK, MDT: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, Cochlear's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cochlear 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cochlear's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Cochlear's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cochlear (CHEOY) has a 3-1 Month Momentum % of 25.04% as of Sep. 21, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Cochlear and its competitors. According to the industry distribution chart, Cochlear ranks #106 out of 847 companies in the Medical Devices & Instruments industry, placing it in the top 12.5%.
Is Cochlear's 3-1 Month Momentum % too high?
Cochlear's current 3-1 Month Momentum % is 25.04%. The Medical Devices & Instruments industry median 3-1 Month Momentum % is 0.61. Cochlear's value of 25.04% is 4004.9% above this industry median. Based on the distribution chart, Cochlear ranks #106 out of 847 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Cochlear has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cochlear's 3-1 Month Momentum % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cochlear ranks #106 out of 847 companies for 3-1 Month Momentum %. This places Cochlear in the top 13% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 0.61. Cochlear's value of 25.04% is 4004.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
The median 3-1 Month Momentum % among Medical Devices & Instruments companies is 0.61, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cochlear's current 3-1 Month Momentum % of 25.04% is 4004.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Cochlear and its competitors. For the Medical Devices & Instruments industry, the median 3-1 Month Momentum % is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cochlear's current 3-1 Month Momentum % is 25.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cochlear stock overvalued right now?
Based on GuruFocus' analysis, Cochlear (CHEOY) is currently considered Significantly Undervalued. The stock's GF Value™ is $105.08, compared to a current price of $47.40 — trading 54.9% below its estimated fair value. The current 3-1 Month Momentum % is 25.04% and 4004.9% above the Medical Devices & Instruments industry median of 0.61. Cochlear's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Cochlear (CHEOY), the current 3-1 Month Momentum % is 25.04% as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cochlear (CHEOY) Overvalued in 2026?
Based on GuruFocus' analysis, Cochlear stock appears to be undervalued.
The current stock price of $47.40 is trading 54.9% below its estimated GF Value™ of $105.08.
GuruFocus considers Cochlear to be Significantly Undervalued.
Key valuation signals for CHEOY:
3-1 Month Momentum %: 25.04%
GF Value™: $105.08 vs. price of $47.40 (54.9% below fair value)
Industry Position: 4004.9% above the Medical Devices & Instruments median (#106 of 847)
No single metric tells the full story. See the CHEOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment.
68GF Score
Get the complete analysis for CHEOY
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHEOY has been successfully added to your 
